デフォルト表紙
市場調査レポート
商品コード
1138337

多血小板血漿(PRP)の世界市場-2022-2029

Global Platelet Rich Plasma Market - 2022-2029

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.87円
多血小板血漿(PRP)の世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

様々な用途に利用される新たな多血小板血漿(PRP)療法が市場成長の原動力になると予想されます。

多血小板血漿療法は、治療や処置のための優れた新たな選択肢と考えられています。血小板が豊富な血漿療法は、最近、美容手術での使用が増えているため、臨床の場で広く使用されています。また、皮膚科医や形成外科医は、多血小板血漿の自然治癒力を利用して、皮膚の外観や健康状態を改善します。また、顔の若返りにも使用されており、その効果も期待されています。純粋な多血小板血漿は、組織の形成と修復が早く、治癒が早く、全体的な性能が高いなどの利点もあるため、使用されています。また、副作用が少なく、免疫反応やアレルギー反応のリスクも低いことから、血小板増加型血漿の市場は急速に上昇すると予想されています。このように、上記の記述から予測期間において市場が牽引されることが予想されます。

制約事項

多血小板血漿療法には高い価格変動があり、創傷治療機器における有利な償還政策があります。さらに、品質管理や検査所見の問題、多血小板血漿療法に伴う欠点は、治療部位の神経損傷、組織損傷、感染症を誘発します。したがって、上記の記述から予測期間中に市場が阻害されることが予想されます。

COVID-19の影響分析

COVID-19のパンデミックは、市場にポジティブな影響を与えました。その治療に利用できる特定の抗ウイルス剤はありません。コロナウイルス感染症2019(COVID-19)では、血栓塞栓症の合併症が頻繁に観察されます。一方、COVID-19は血小板の調節異常と関連しています。COVID-19の有害転帰は、基礎的な血小板活性化の増加や血小板反応の減弱と関連しており、これらは時間の経過とともに悪化していきました。COVID-19の発生により、血小板が呼吸器系障害の排除と肺の機能維持に重要な役割を果たすため、多血小板血漿療法がコロナウイルス治療に使用され、多血小板血漿療法の需要は大幅に増加しました。例えば、適応免疫療法の代表格である回復期血漿(CP)療法は、1世紀以上にわたって多くの感染症の予防と治療に適用されてきました。過去20年間、CP療法はSARS、MERS、2009年のH1N1パンデミックを満足のいく効果と安全性で治療することに成功しました。したがって、これは予測期間の多血小板血漿市場を後押しするためです。

産業分析

多血小板血漿市場は、アンメットニーズ、価格分析、サプライチェーン分析、規制分析などの様々な産業要因に基づいて、市場の詳細な分析を提供します。

世界の多血小板血漿市場レポートは、約45+市場データ表、40+図、180ページの構成で提供しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

  • タイプ別市場内訳
  • アプリケーション別市場内訳
  • 原産地別市場内訳
  • エンドユーザー別市場内訳
  • 地域別市場内訳

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 様々な用途で活用される多血小板血漿(PRP)療法の台頭により、市場の成長が見込まれます。
    • 抑制要因
      • 多血小板血漿に関連する欠点が市場成長の妨げになると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • サプライチェーン分析
  • 価格設定分析
  • 法規制の分析
  • アンメットニーズ

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 タイプ別

  • 純粋な多血小板血漿
  • 白血球増加型PRP
  • 白血球リッチフィブリン
  • その他

第8章 用途別

  • 整形外科
  • 美容外科・皮膚科
  • 神経内科
  • 循環器領域
  • 眼科
  • その他

第9章 由来別

  • 自己由来PRP
  • 自家PRP
  • 同種PRP
  • その他

第10章 エンドユーザー別

  • 病院
  • クリニック
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 世界の多血小板血漿市場-企業プロファイル

  • Zimmer Biomet
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Johnson & Johnson(DePuy Synthes)
  • Arthrex Inc.
  • Terumo BCT Inc.
  • Celling BioSciences
  • APEX Biologix
  • Juventix
  • Dr. PRP America
  • Stryker
  • Ycellbio Medical Co., Ltd(*LIST NOT EXHAUSTIVE)

第14章 DataM

目次
Product Code: DMMD1333

Market Overview

Platelet Rich Plasma Market is expected to grow at a CAGR of 13.88% during the forecasting period (2022-2029).

Platelet-rich plasma (PRP) is derived from blood. It's made when human blood is spun down and platelet-rich plasma, which has a higher concentration of platelets than normal, is extracted. Platelets assist in blood clotting and assist tendons, muscles, and ligaments repair faster. PRP is used in various operations, including rotator cuff augmentation and tendon repair. Healing factors and connective tissue development is abundant in platelets.

Market Dynamics

Emerging platelet-rich plasma (PRP) therapy utilized for various applications is expected to drive market growth.

Platelet-rich plasma therapy is considered a superior emerging choice for therapy and procedures. Platelet-rich plasma therapy has recently been widely used in clinical settings, owing to increased use in cosmetic operations. In addition, dermatologists and plastic surgeons use platelet-rich plasma's natural healing qualities to improve the appearance and health of the skin. Its usage in face rejuvenation has also yielded promising effects. Pure platelet-rich plasma is also used because of its benefits, such as faster tissue formation and repair, faster healing, and greater overall performance. Also, with fewer side effects and a lower risk of immunological reaction and allergic reactions, the Platelet Rich Plasma market is expected to rise rapidly. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

There is high price variability in platelet-rich plasma therapy and favorable reimbursement policies in wound care equipment. Furthermore, issues with quality control and test findings and drawbacks associated with platelet-rich plasma therapy induce nerve damage, tissue damage, and infection in the treatment region. Therefore, the market is expected to get hampered in the forecast period from the above statements.

COVID-19 Impact Analysis

The COVID-19 pandemic had a positive impact on the market. There are no specific antiviral agents available for its treatment. Thromboembolic complications are frequently observed in Coronavirus disease 2019 (COVID-19). In contrast, COVID-19 is linked to platelet dysregulation. An adverse outcome in COVID-19 was associated with increased basal platelet activation and diminished platelet responses, which aggravated over time. Due to the covid-19 outbreak, platelet-rich plasma therapy was used to treat coronavirus as platelets play a vital role in eliminating respiratory disorders and maintaining the functioning of the lungs due to the demand for platelet-rich plasma therapy has significantly increased. For instance, Convalescent plasma (CP) therapy, classic adaptive immunotherapy, has been applied to prevent and treat many infectious diseases for more than one century. Over the past two decades, CP therapy successfully treated SARS, MERS, and the 2009 H1N1 pandemic with satisfactory efficacy and safety. Thus, this is due to boosting the forecast period's platelet-rich plasma market.

Industry Analysis

The platelet rich plasma market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Pure Platelet Rich Plasma segment is expected to hold the largest market share in the platelet-rich plasma market.

The pure platelet-rich plasma segment accounted for the largest market share in 2021. The segment benefits because it has rapid healing, tissue repair and production, and general function improvement, which have enhanced its demand across several treatment business spaces, adding to segment expansion. In pure PRP therapeutic approaches, entities in the market are paying attention to effectively eliminating dangers and unwanted effects, such as allergic or immunological reactions. PRP's present off-label use has prompted numerous manufacturers worldwide to produce various sorts of products, owing to its tremendous promise in treating various chronic illnesses. For instance, Celling Biosciences is dedicated to the scientific understanding and therapeutic application of autologous cell therapy, which includes ART PRP product which is widely used in orthopedic and sports medicine to relieve pain through the natural promotion of healing in musculoskeletal diseases such as tendonitis, arthritis, ligament sprains, and tears. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North American region is expected to hold the largest market share in the global platelet rich plasma market.

In 2021, North America accounted for the highest revenue share. The increasing number of cosmetic surgeries, high awareness about platelet-rich plasma-based treatments, technological advancement, well-established infrastructure, product launches and approvals by the market players are some factors that the market is expected to boost in the forecast period. For instance, with approximately four million cosmetic treatments performed in 2020, the United States will have the highest number of cosmetic procedures globally. Over the last decade, the number of surgical and nonsurgical cosmetic treatments performed in the United States has increased, from over 1.6 million in 1997 to over 5.5 million in 2020. Moreover, EmCyte acquired Cellmedix Holdings LLC in February 2020, acquiring all of the latter's assets, including its proprietary product system, the Centrepid Platelet Concentrator. EmCyte's product development skills and intellectual property profile will be enhanced as a result of this strategic purchase. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the platelet-rich plasma market are Zimmer Biomet, Johnson & Johnson (DePuy Synthes), Arthrex Inc., Terumo BCT Inc., Celling BioSciences , APEX Biologix, Juventix, Dr. PRP America, Stryker and Ycellbio Medical Co., Ltd.

Johnson & Johnson (DePuy Synthes):

Overview:

Johnson & Johnson (DePuy Synthes) designs, manufacture, and markets various orthopedic and neurological devices globally. The company is involved in developing medical devices for diagnosing damaged joints and repairing reconstructing skeletal injuries. It has a comprehensive portfolio of orthopedic products and neuro products, and it focuses on the therapeutic areas of spinal care, orthopedics, sports medicine, and neurosciences. It offers products, services, programs, and R&D capabilities to advance patient care and adds clinical and economic value to healthcare systems. In many countries, the company operates under the name of Johnson and Johnson.

Product Portfolio:

PEAK Platelet Rich Plasma System: The PEAK Platelet Rich Plasma System represents an option in autologous cellular therapies featuring a vertical roto centrifugation process. The proprietary technology consistently delivers 3 ml of 7.8x high-concentration platelet rich plasma (PRP) from 27 ml of whole blood within 2.5 minutes.

The global Platelet rich plasma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Origin
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Emerging platelet-rich plasma (PRP) therapy utilized for various applications is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The drawbacks associated with platelet-rich plasma are expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Pure Platelet Rich Plasma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Leukocyte Rich PRP
  • 7.4. Leukocyte-Rich Fibrin
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Orthopedics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Cosmetic Surgery and Dermatology
  • 8.4. Neurology
  • 8.5. Cardiology
  • 8.6. Ophthalmology
  • 8.7. Others

9. By Origin

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 9.1.2. Market Attractiveness Index, By Origin Segment
  • 9.2. Autologous PRP*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Homologous PRP
  • 9.4. Allogeneic PRP
  • 9.5. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Global Platelet-rich Plasma Market- Company Profiles

  • 13.1. Zimmer Biomet*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Johnson & Johnson (DePuy Synthes)
  • 13.3. Arthrex Inc.
  • 13.4. Terumo BCT Inc.
  • 13.5. Celling BioSciences
  • 13.6. APEX Biologix
  • 13.7. Juventix
  • 13.8. Dr. PRP America
  • 13.9. Stryker
  • 13.10. Ycellbio Medical Co., Ltd(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us